Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.

1996 ◽  
Vol 14 (6) ◽  
pp. 1765-1769 ◽  
Author(s):  
P C Brenner ◽  
H W Herr ◽  
M J Morse ◽  
J Sheinfeld ◽  
A Aprikian ◽  
...  

PURPOSE We report our experience with simultaneous resection of residual masses above and below the diaphragm in patients with metastatic nomseminomatous germ cell tumor (NSGCT) of the testis. MATERIALS AND METHODS Twenty-four patients underwent simultaneous resection of residual postchemotherapy masses in the retroperitoneum and chest, including three who also had radical neck dissection. All had been heavily pretreated with chemotherapy and five had undergone previous retroperitoneal lymph node dissections (RPLNDs). RESULTS The combined procedure was performed with no mortality and low morbidity. The median length of the procedure was 5 hours 45 minutes, median blood loss 500 mL, and median length of hospital stay 9 days. Complications included one patient with chylous ascites and one with a prolonged air leak, both of which resolved with conservative management. Eighteen patients had similar pathologic findings in all sites: 13 with necrosis only and five with teratoma only. Six patients had discordant pathology in the abdomen and chest, including one with viable tumor in the chest only and two with viable tumor in the abdomen only. The overall actuarial 5-year survival rate for all patients was 79%. CONCLUSION Simultaneous resection of neck, chest, and abdominal residual masses after chemotherapy for germ cell tumors is both a feasible and safe alternative to staged excision in selected patients who require surgical intervention at multiple sites and fulfills the objective of rendering patients disease-free in a single operative procedure.

2019 ◽  
Vol 19 (4) ◽  
pp. 291-300 ◽  
Author(s):  
Axel Heidenreich ◽  
Pia Paffenholz ◽  
Tim Nestler ◽  
David Pfister

2004 ◽  
Vol 22 (2) ◽  
Author(s):  
AnnaC. Pfannenberg ◽  
Karin Oechsle ◽  
Carsten Bokemeyer ◽  
Christian Kollmannsberger ◽  
BernhardM. Dohmen ◽  
...  

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 389-389
Author(s):  
Siwat Sakdejayont ◽  
Chirawadee Sathitruangsak ◽  
Patrapim Sunpaweravong ◽  
Arunee Dechaphunkul

389 Background: Mediastinal germ cell tumors (MGCTs) account for 20% of all mediastinal tumors. Cisplatin-based chemotherapy followed by surgical resection of residual tumor remains the standard of care. To prevent pulmonary complications secondary to extensive thoracic surgery, non-bleomycin containing regimen is generally preferred. This study aims to review clinical characteristics and outcomes of these patients. Methods: A retrospective chart review was undertaken in patients with MGCTs treated in our institution between 1993 and 2013. Results: A total of 40 patients were enrolled with a median age of 24. Only one patient is female. Stratified by histology; eight patients (20%) had pure seminoma, 25 patients (62.5%) had pure non-seminoma, four patients (10%) had mixed seminoma and non-seminoma, and three patients (7.5%) had malignant transformation (two adenocarcinoma, one sarcoma). Median tumor size was 13 centimeters. Ninety-two percent of patients received chemotherapy as a first treatment modality, whereas 8% underwent upfront surgery. All patients received cisplatin-based chemotherapy: Eighty seven percent bleomycin, etoposide and cisplatin; 13% etoposide and cisplatin. Seventy-two percent of patients completed four planned cycles of chemotherapy. Thirty-one patients were able to assess radiological response: 3.2% complete response, 58.1% partial response, 29.0% stable disease, and 9.7% progressive disease. Forty-four percent of patients achieved completely serological response with chemotherapy. Seventeen patients underwent surgical resection of residual tumor. Among these, viable tumor was seen in 35% (6 out of 17 patients). No patients complicated with clinically significant pulmonary complications after thoracic surgery. The five year overall survival (OS) of patients with seminoma was 72.9% as compared with 19.9% in those with non-seminoma (p=0.012). For those who received chemotherapy followed by surgical resection with no viable tumor or only mature teratoma detected (N=11), the five year OS was 64.9%. Conclusions: Our study confirmed the importance of multi-modality approaches with primary chemotherapy followed by surgical resection of residual tumor. Bleomycin-containing regimen can be safely used in this setting.


2020 ◽  
Vol 26 (1) ◽  
pp. 186-191
Author(s):  
Mesut Altan ◽  
Hakan Bahadır Haberal ◽  
Ahmet Aşçı ◽  
Ahmet Güdeloğlu ◽  
Ahmet Bülent Doğrul ◽  
...  

1997 ◽  
Vol 8 (6) ◽  
pp. 531-538 ◽  
Author(s):  
J.T. Hartmann ◽  
H.-J. Schmoll ◽  
M.A. Kuczyk ◽  
M. Candelaria ◽  
C. Bokemeyer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4525-4525
Author(s):  
P. Maroto-Rey ◽  
X. García Del Muro ◽  
L. Paz-Ares ◽  
E. Alba ◽  
J. Sastre ◽  
...  

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15617-e15617
Author(s):  
Elena Almagro ◽  
David Perez ◽  
Judit Rubio ◽  
Fernando Franco ◽  
Magda Palka ◽  
...  

2013 ◽  
Vol 12 (6) ◽  
pp. 178
Author(s):  
C. Baena Villamarin ◽  
C. Corchuelo Maillo ◽  
M. Alonso García ◽  
J.M. Conde Sánchez ◽  
I. Durán ◽  
...  

Urology ◽  
2001 ◽  
Vol 57 (2) ◽  
pp. 323-327 ◽  
Author(s):  
Haluk Özen ◽  
Si̇nan Eki̇ci̇ ◽  
Si̇nan Sözen ◽  
Ali̇ Ergen ◽  
Serdar Tekgül ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document